Loading clinical trials...
Loading clinical trials...
Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers
Conditions
Interventions
MV-CHIK low dose
MV-CHIK high dose
+2 more
Locations
4
Austria
Hansa Sanatorium GmbH
Graz, Austria
Medical University Vienna, Department of Clinical Pharmacology
Vienna, Austria
Berliner Center for Travel- and Tropical Medicine
Berlin, Germany
Medicinal University Rostock, Department for Tropical Medicin and infectious diseases
Rostock, Germany
Start Date
August 17, 2016
Primary Completion Date
September 1, 2017
Completion Date
April 16, 2018
Last Updated
October 29, 2021
Lead Sponsor
Themis Bioscience GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions